NPCE Share Price Performance
US$14.58
2.77 (23.45%)
25.0% undervalued intrinsic discount
US$19.43
Fair Value
Price US$14.58
AnalystConsensusTarget US$19.43
AnalystHighTarget US$22.00
AnalystLowTarget US$15.63
Fair ValueUS$19.43
Share Pricen/a
NeuroPace, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
NPCE Community Narratives
AN
Fair Value US$19.43 25.0% undervalued intrinsic discount
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$22 33.7% undervalued intrinsic discount
Aging Global Population And Advanced Neurostimulation Will Expand Treatment Options
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$15.63 6.7% undervalued intrinsic discount
Rising Regulatory Pressures Will Undermine Neurotech And Spur Cautious Optimism
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Rising Regulatory Pressures Will Undermine Neurotech And Spur Cautious Optimism
Key Takeaways Persistent pricing pressure, data privacy concerns, and a limited addressable market threaten revenue growth and sustainable operating margins. Industry shifts toward non-invasive solutions and substantial investment needs may undermine sales volume, profitability, and long-term cash flow.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$15.63
6.7% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
18.2% p.a.
Profit Margin
12.98%
Future PE
32.88x
Price in 2029
US$19.17
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
Key Takeaways Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery. AI-enhancements and clinical program advancements promise operational efficiency, new revenue streams, and improved financial performance.Read more
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$19.43
25.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
11.46% p.a.
Profit Margin
12.92%
Future PE
50.42x
Price in 2029
US$24.53
Aging Global Population And Advanced Neurostimulation Will Expand Treatment Options
Key Takeaways Accelerated adoption in epilepsy centers and new indications could rapidly expand NeuroPace's accessible market, driving sustained outperformance versus expectations. Proprietary EEG data and AI analytics are opening lucrative recurring revenue streams and supporting long-term margin improvement.Read more
17
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$22
33.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
18.63% p.a.
Profit Margin
3.04%
Future PE
200.98x
Price in 2029
US$27.77
Trending Discussion
Recently Updated Narratives
AN
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Fair Value: US$15.63 6.7% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NPCE: Updated Seizure Trial Data Will Support A More Optimistic Outlook
Fair Value: US$19.43 25.0% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NPCE: Broader Epilepsy Indication And Trial Evidence Will Support Future Upside
Fair Value: US$22 33.7% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
NeuroPace, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Mar 03, 2026
- -0.72
- 76.77%
- -25.28%
- 317.2%
About NPCE
- Founded
- 1997
- Employees
- 209
- CEO
- WebsiteView website
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
